Sanofi presses on with threat to oust Medivation's board
The sources asked not to be identified because the deliberations are confidential. Sanofi, Medivation, Goldman Sachs and Pfizer declined to comment.13-05-2016
13-05-2016
Clarification
Sanofi India Ltd has informed BSE that :"The Business Standard has published an article today on recall of some batches of the Company's product Combiflam.The newspaper sought our comments on the issue which were provided to them. Our clarifications have been published in the said article.In response to further queries received from the media, the following additional clarifications are being provided by the Company:...12-05-2016
Sanofi recalls batches of Combiflam tablets in India
DCGI had issued safety alerts after some batches of Combiflam did not meet the standards due to delayed disintegration of the molecule in the blood stream11-05-2016
Health Ministry panel rejects Sanofi's clinical waiver plea for dengue vaccine
NEW DELHI: French drug and vaccines giant Sanofi suffered a setback in introducing its muchawaited dengue vaccine Dengvaxia in India after a top health ministry committee rejected its request to waive additional clinical studies. The decision of the apex committee is expected to delay the entry of the vaccine, which has been approved in Mexico, the Philippines and Brazil to combat the mosquito-borne disease. The race to beat dengue is picking up momentum, though. Sun Pharmaceuticals, India's largest drug maker, announced on Wednesday a partnership with nonprofit research organisation International Centre for Genetic Engineering and Biotechnology (ICGEB) to develop a botanical drug to fight the dengue virus. The apex committee's decision comes after two other panels granted exemptions for conducting local phase-III clinical trials for the vaccine called Dengvaxia, according to the recently released minutes of its April 6 and April 11meetings. The subject expert committee (SEC) and the technical committee had backed Sanofi's request for a waiver on the basis of approvals received in other countries and exhaustive phase-II studies in India. India has a three-level approval process for new drugs and vaccines, with applications scrutinised by SEC, technical committee and the apex committee. Although the Sanofi vaccine does...05-05-2016
Speech of the Managing Director delivered at the Annual General Meeting held on April 29, 2016
Sanofi India Ltd has submitted to BSE a copy of the Speech of the Managing Director, Dr. Shailesh Ayyangar delivered at the Annual General Meeting held on April 29, 2016.02-05-2016
Annual General Meeting held on April 29, 2016- Voting Results
Sanofi India Ltd has informed BSE regarding "Annual General Meeting held on April 29, 2016- Voting Results".30-04-2016
Announces Q1 Results (Standalone) & Limited Review Report (Standalone) for the period ended March 31, 2016
Sanofi India Ltd has announced the following Unaudited Standalone Financial results for the quarter ended March 31, 2016:The Company has posted a net profit of Rs. 806 million for the quarter ended March 31, 2016 as compared to Rs. 645 million for the quarter ended March 31, 2015. Total Income has increased from Rs. 5083 million for the quarter ended March 31, 2015 to Rs. 5700 million for the quarter ended March 31, 2016.29-04-2016
Sanofi makes $9.3 bn bid for US firm Medivation
Sanofi Chief Executive Olivier Brandicourt says in an open letter to Medivation's CEO David T. Hung that the all-cash offer is for $52.50 per share.28-04-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016
Sanofi India Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.21-04-2016
Shareholding for the Period Ended March 31, 2016
Sanofi India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2016. For more details, kindly Click here19-04-2016